Xeris Biopharma director granted stock and options

Xeris Biopharma Holdings director Nerissa Kreher received equity-based compensation.

Rhea-AI Filing Summary

Xeris Biopharma Holdings director Nerissa Kreher received equity-based compensation. She was granted 33,582 shares of common stock through restricted stock units under the company’s 2018 Stock Option and Incentive Plan. These RSUs vest in equal annual installments over three years, contingent on continued board service.

She was also granted stock options for 37,910 shares of common stock at an exercise price of $8.00 per share, expiring on July 1, 2036. These options vest in equal annual installments over three years, also subject to continued service on the board. The filing shows no open-market buying or selling, only compensation-related awards.

Insider Trade Summary

Grant/Award: 71,492 shares

Grant/Award 2 txns

Insider KREHER NERISSA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	37,910	$8.00	$303K
Grant/Award	Common Stock	33,582	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 37,910 contracts (Direct); Common Stock — 33,582 shares (Direct)

Footnotes (2)

1. F1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.
2. F2. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.

Key Figures

RSU grant: 33,582 shares Option grant size: 37,910 options Option exercise price: $8.00 per share +3 more

6 metrics

RSU grant 33,582 shares Restricted stock units granted to director as of July 1, 2026

Option grant size 37,910 options Stock options granted on common stock as of July 1, 2026

Option exercise price $8.00 per share Strike price for stock options granted to director

Option expiration July 1, 2036 Expiration date of granted stock options

Common shares after RSU grant 33,582 shares Total common stock holdings following RSU transaction

Options after grant 37,910 options Total derivative holdings following option grant

Key Terms

restricted stock unit, 2018 Stock Option and Incentive Plan, vest in equal annual installments, Stock Option (Right to Buy), +1 more

5 terms

restricted stock unit financial

"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

2018 Stock Option and Incentive Plan financial

"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"

vest in equal annual installments financial

"These shares shall vest in equal annual installments over three years, subject to continued service"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) transaction reported as a derivative security grant"

exercise price financial

"These stock options were acquired pursuant to a grant under the Plan with an $8.00 exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Xeris Biopharma (XERS) director Nerissa Kreher report in this Form 4?

Director Nerissa Kreher reported equity compensation awards, not open-market trades. She received 33,582 restricted stock units and stock options for 37,910 shares, all granted under Xeris Biopharma’s 2018 Stock Option and Incentive Plan as part of her board compensation.

How many Xeris Biopharma shares did Nerissa Kreher acquire as restricted stock units?

She acquired 33,582 restricted stock units, each representing one share of Xeris Biopharma common stock. These units are a form of stock-based compensation and will convert into shares only as they vest, conditioned on her continued service on the company’s board of directors.

What stock options were granted to Nerissa Kreher by Xeris Biopharma (XERS)?

She received stock options covering 37,910 shares of Xeris Biopharma common stock at an exercise price of $8.00 per share. The options were granted as compensation and give her the right, but not obligation, to buy shares before the July 1, 2036 expiration date.

How do the vesting terms work for Nerissa Kreher’s Xeris Biopharma equity awards?

Both the 33,582 restricted stock units and the 37,910 stock options vest in equal annual installments over three years. Vesting is contingent on Nerissa Kreher’s continued service on Xeris Biopharma’s board, meaning she earns portions of the awards each year she remains a director.

Did Nerissa Kreher buy or sell Xeris Biopharma (XERS) shares on the open market?

No open-market purchases or sales were reported. The Form 4 shows only awards coded as acquisitions (A): grants of restricted stock units and stock options as director compensation, with no indication of discretionary buying or selling in the company’s shares on the market.

When do Nerissa Kreher’s Xeris Biopharma stock options expire and at what price?

Her stock options expire on July 1, 2036 and have an exercise price of $8.00 per share. She can choose to exercise them before that date, subject to vesting, to purchase Xeris Biopharma common shares at that fixed price regardless of future market prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 06:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KREHER NERISSA

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		33,582(1)	A	$0	33,582	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8	07/01/2026		A		37,910		(2)	07/01/2036	Common Stock	37,910	$8	37,910	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.

2. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.

Remarks:

Director

	/s/ Beth Hecht, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)